Development of new treatments for lung disease

Respiratory Medicine

Volumn 90, Issue 1, 1996, Pages 5-23

  Tetley, T D ^a   Rogers, D F ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMAKALIM; DEOXYRIBONUCLEASE; ENDOTHELIN 1; ETHAMBUTOL; GLUCOCORTICOID; ISONIAZID; PYRAZINAMIDE; RANITIDINE; RIFAMPICIN; STREPTOMYCIN; THEOPHYLLINE; THIOACETAZONE; TRANSFORMING GROWTH FACTOR; ZAFIRLUKAST;

ALPHA 1 ANTITRYPSIN DEFICIENCY; CONFERENCE PAPER; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; GENE THERAPY; HEADACHE; HEART GRAFT; HUMAN; LUNG DISEASE; LUNG FIBROSIS; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SUBSTITUTION THERAPY; TUBERCULOSIS; VIRUS INFECTION;

EID: 0029879929     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(96)90240-1     Document Type: Conference Paper

References (119)

1. DiMasi JA. Risks, regulation, and rewards in new drug development in the United States. Regulatory Toxicol Pharmacol 1994; 19: 228-235.
2. DiMasi JA, Seibring MA, Lasagna L. New drug development in the United States from 1963 to 1992. Clin Pharmacol Ther 1994; 55: 611-622.
3. Grabowski H, Vernon J. A new look at the returns and risks to pharmaceutical R&D. Management Sci 1990; 36: 804-821.
4. Bohacek RS, McMartin C. Exploring the universe of molecules for new drugs. Nature Med 1995; 1: 177-178.
5. Duchin JS, Koster FT, Peters CJ et al. Hantavirus syndrome: a clinical description of 17 patients with newly recognised disease. New Engl J Med 1994; 330: 949-955.
6. Levy H, Simpson SQ. Hantavirus pulmonary syndrome. Am J Respir Crit Care Med 1994; 149: 1710-1713.
7. Han LY, Wilson R, Slater S et al. In vitro and in vivo effects of ribavirin on human respiratory epithelium. Thorax 1990; 45: 100-104.
8. Snell NJC. Delivery of antiviral medication via a small particle aerosol generator (SPAG). J Aerosol Med 1991; 4 (suppl 1): 16.
9. Capsey LJ, Jones KL, Snell NJC. Safety and tolerance of nebulised ribavirin in clinical usage. Acta Ther 1992; 18: 133-147.
10. Higgins PG, Barrow GI, Tyrrell DAJ, Snell NJC, Jones K, Jolley WB. A study of the immunomodulatory compound 7-thia-8-oxoguanosine in coronavirus 229E infections in human volunteers. Antiviral Chem Chemother 1991; 2: 61-64.
11. Proud D, Gwalney JM Jr, Hendley JO, Dinarello CA, Gillis S, Schleimer RP. Increased levels of interleukin-1 are detected in nasal secretions of volunteers during experimental rhinovirus colds. J Infect Dis 1994; 169: 1007-1013.
12. Hendley JO, Abbott RD, Beasley PP, Gwaltney JM Jr. Effect of inhalation of hot humidified air on experimental rhinovirus infection. J Am Med Assoc 1994; 271: 1112-1113.
13. Woods et al. 4-guanidino Neu5Ac 2en (GR 121167). Antimicrob Agents Chemother 1993; 37: 1473.
14. Rieder HL. Drug-resistant tuberculosis: issues in epidemiology and challenges for public health. Tubercle Lung Dis 1993; 75: 321-323.
15. Iseman MD. Treatment of multidrug-resistant tuberculosis. New Engl J Med 1993; 329: 784-791.
16. Iseman MD. Evolution of drug-resistant tuberculosis: A tale of two species. Proc Natl Acad Sci USA 1994; 91: 2428-2429.
17. Walker DA, Taylor IK, Mitchell DM, Shaw RJ. Comparison of polymerase chain reaction amplification of two mycobacterial DNA sequences, IS6110 and the 65kDa antigen gene, in the diagnosis of tuberculosis. Thorax 1992; 47: 690-694.
18. Goyal M, Ormerod LP, Shaw RJ. Epidemiology of an outbreak of drug-resistant tuberculosis in the UK using restriction fragment length polymorphism. Clin Sci 1994; 86: 749-751.
19. Stanford JL, Grange JM. The promise of immunotherapy for tuberculosis. Respir Med 1994; 88: 3-7.
20. Hodson ME. Cystic fibrosis: the disease. Monaldi Arch Chest Dis 1993; 48: 647-652.
21. Riordan JR. The cystic fibrosis transmembrane conductance regulator. Annu Rev Physiol 1993; 55: 609-630.
22. Alton E, Geddes D. Gene therapy for cystic fibrosis: a clinical perspective. Gene Therapy 1995; 2: 1-8.
23. Elborn JS, Shale DJ, Britton JR. Cystic fibrosis: current survival and population estimate to the year 2000. Thorax 1991; 46: 881-885.
24. Knowles MR, Church NL, Waltner WE et al. A pilot study of aerosolised amiloride for the treatment of lung disease in cystic fibrosis. New Engl J Med 1990; 322: 1189-1194.
25. Graham A, Hasani A, Alton EWFW et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993; 6: 1243-1248.
26. Engelhardt JF, Yankaskas JR, Ernst SA et al. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nature Genetics 1992; 2: 240-248.
27. Engelhardt JF, Zepeda M, Cohn JA, Yankaskas JR, Wilson JM. Expression of the cystic fibrosis gene in adult human lung. J Clin Invest 1994; 93: 737-749.
28. Trapnell BC, Chu C-S, Paakko PK et al. Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis. Proc Natl Acad Sci USA 1991; 88: 6565-6569.
29. Crawford I, Maloney PC, Zeitlin PL et al. Immunocytochemical localisation of the cystic fibrosis gene product CFTR. Proc Natl Acad Sci USA 1991; 88: 9262-9266.
30. Crystal R. The gene as the drug. Nature Med 1995; 1: 15-17.
31. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia with cystic fibrosis. Cell 1993; 75: 207-216.
32. Caplen NJ, Alton EWFW, Middleton PG et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature Med 1995; 1: 39-46.
33. Zhu N, Liggitt D, Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science 1993; 261: 209-211.
34. Dodge JA. Gene therapy for cystic fibrosis. Nature Med 1995; 3: 182.
35. Aitken ML. Clinical trials of recombinant human DNase in cystic fibrosis patients. Monaldi Arch Chest Dis 1993; 48: 653-656.
36. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188-9192.
37. Green JD. Pharmacological-texicological expert report: Pulmozyme (rhDNase). Human Exp Toxicol 1994; 13: S1-S42.
38. Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith AL. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase I study. J Am Med Assoc 1992; 267: 1947-1951.
39. Hubbard RC, McElvany NG, Birrer P et al. A preliminary study of aerosolised recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. New Engl J Med 1992; 326: 812-815.
40. Ranashinha C, Assoufi B, Shak S et al. Efficacy and safety of short-term administration of aerosolised recombinant human DNase 1 in adults with stable stage cystic fibrosis. Lancet 1993; 342: 199-202.
41. Ramsey BW, Astley SJ, Aitken MI et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148: 141-151.
42. Fuchs HJ, Borowitz DS, Christiansen DH et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. New Engl J Med 1994; 331: 637-642.
43. Wilmott R. A phase II, double-blind, multicentcr study of the safety and efficacy of aerosolised recombinant human DNase I (rhDNase) in hospital patients with CF experiencing acute pulmonary exacerbations. Pediatric Pulmonol; (suppl 9): 154.
44. Shah PL, Scott SF, Hodson ME. Report on multicentre study using aerosolised recombinant human DNase I in patients with severe pulmonary disease. Pediatric Pulmonol 1993; (suppl 9): 157-158.
45. Shah PL, Scott SF, Hodson ME. Lobar atelectasis in cystic fibrosis and treatment with recombinant human DNase I. Respir Med 1994; 88: 313-315.
46. 1-antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15: 132-140.
47. Beatty K, Bieth J, Travis J. Kinetics of association of serine proteinases with native and oxidised alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J Biol Chem 1980; 255: 3931-3934.
48. 1-antitrypsin gene and a disease-associated mutation in a related enhancer sequence. Am J Respir Crit Care Med 1994; 150: 183-189.
49. 1-antitrypsin. Nature 1982; 298: 329-334.
50. 1-antitrypsin accumulation in the liver. Nature 1992; 357: 605-607.
51. Damiano VV, Tsang A, Kucich U, Abrams WR, Rosenbloom J, Kimbel P, Fallahnejad M, Weinbaum G. Immunolocalisation of elastase in human emphysematous lungs, J Clin Invest 1986; 78: 482-493.
52. 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055-1062.
53. Hubbard RC, Crystal RG. Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency. Am J Med 1988; 84 (6A): 52-62.
54. 1-antitrypsin deficiency. Clin Invest 1988; 260: 1259-1264.
55. iZ subjects with chronic obstructive lung disease. Am J Med 1988; 84 (suppl 5A): 63-69.
56. Hubbard RC, Brantly ML, Sellers SE, Mitchell ME, Crystal RG. Anti-neutrophil-elastase defences of the lower respiratory tract in α1-antitrypsin deficiency directly augmented with an aerosol of α1-antitrypsin. Ann Intern Med 1989; 111: 206-212.
57. Hubbard RC, McElvany NG, Sellers SE, Healy JT, Czerski DB, Crystal RG. Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defences in individuals with alpha 1-antitrypsin deficiency. J Clin Invest 1989; 84: 1349-1354.
58. Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung 1990; 168 (suppl): 565-578.
59. Stockley R A, Grant RA, Llewellyn-Jones CG, Hill SL, Burnett D. Neutrophil formyl-peptide receptors. Relationship to peptide-induced responses and emphysema. Am J Respir Crit Care Med 1994; 149 (2 pt 1): 464-468.
60. Burnett D, Chamba A, Hill SL, Stockley RA. Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis. Lancet 1987; 2: 1043-1046.
61. Rosenfeld MA, Siegfried W, Yoshimura K et al. Adenovirus-mediated transfer of a recombinant α1-antitrypsin gene to the lung epithelium in vivo. Science 1991; 252: 431-434.
62. Barnes PJ, Pauwels RA. Theophylline in the management of asthma: time for reappraisal? Eur Respir J 1994; 7: 579-591.
63. Barnes PJ. Antiinflammatory therapy for asthma. Ann Rev Med 1993; 44: 21-50.
64. 2-agonists in asthma therapy. Trends Pharmacol Sci 1992; 13: 20-23.
65. 2. Lancet 1995; 345: 435-438.
66. Torphy TJ. β-Adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma. Trends Pharmacol Sci 1994; 15: 370-374.
67. Black JL, Barnes PJ. Potassium channels and airway function: new therapeutic approaches. Thorax 1990; 45: 213-218.
68. + channels. Exp Opin Invest Drugs 1994; 3: 1181-1188.
69. Ca channel opener, in vascular smooth muscle. Br J Pharmacol 1994; 113: 1538-1547.
70. Chung KF, Barnes PJ. Role of inflammatory mediators in asthma. Br Med Bull 1992; 48: 135-148.
71. Spence DPS, Johnston SL, Calverley PMA et al. The effect of the orally active platelet activating factor antagonist in the treatment of asthma. Am J Respir Crit Care Med 1994; 149: 1142-1148.
72. Kuitert LM, Angus RM, Barnes NC et al. A placebocontrolled study of a novel potent PAF antagonist, modipafant, in clinical asthma. Am J Respir Crit Care Med 1995; 151: 1331-1335.
73. Chung KF. Leukotriene receptor antagonist and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J 1995; 8: 1203-1213.
74. Spector SL, Smith LJ, Glass M et al. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 618-623.
75. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993; 148: S1-S26.
76. Brattsand R, Axelsson BI. New inhaled glucocorticosteroids. In: Barnes PJ, ed. New Drugs for Asthma, Vol. 2. London: PJ, IBC Technical Services Limited, 1992, pp. 193-208.
77. Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol Sci 1993; 14: 436-441.
78. Dent G, Giembycz MA. Selective phosphodiesterase inhibitors in the therapy of asthma. Clin Immunotherapies 1995; 3: 423-437.
79. Crompton GK. The adult patient's difficulties with inhalers. Lung 1990; 168 (suppl): 658-662.
80. Rogers DF, Ganderton D. Determining equivalence of inhaled medications. Respir Med 1995; 89: 253-261.
81. Newman SP. Delivery systems. In: Barnes PJ, ed. New Drugs for Asthma, Vol. 2. London: IBC Technical Services Limited, 1992, pp. 245-257.
82. Newman SP, Clarke SW. Bronchodilator delivery from Gentlehaler, a new low-velocity pressurised aerosol inhaler. Chest 1993; 103: 1442-1446.
83. Jäger-Waldau R. Feasibility of drug delivery to the respiratory tract by a mechanical spray pump. J Aerosol Med 1994; 7: 147-154.
84. Jäger-Waldau R, Mehring H, Wiggins JD. A mechanical micro spray pump: an alternative to propellant driven devices? J Aerosol Med 1994; 7: 189-192.
85. Jäger-Waldau R, Mehring R, Wiggins JD. Feasibility of a low dosage dynamic powder dispenser for drug delivery to the lungs. J Aerosol Med 1994; 7: 205-208.
86. Cambrey AD, Harrison NK, Dawes KE et al. Increased levels of endothelin 1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol 1994; 11: 439-445.
87. Harrison NK, Cambrey AD, Myers AR et al. Insulin-like growth factor-1 is partially responsible for fibroblast proliferation induced by bronchoalveolar lavage fluid from patients with systemic sclerosis. Clin Sci 1994; 86: 141-148.
88. Gray AJ, Reeves JT, Harrison NK, Winlove P, Laurent GJ. Growth factors for human fibroblasts in the solute remaining after clot formation. J Cell Sci 1990; 96: 271-274.
89. Bröekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA. 1991; 88: 6642-6646.
90. Gauldie J, Jordana M, Cox G. Cytokines and pulmonary fibrosis. Thorax 1993; 48: 931-935.
91. Corrin B, Butcher D, McAnulty RJ et al. Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 1994; 24: 145-150.
92. Donnelly SC, Strieter RM, Kunkel SL et al. Interleukin 8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet 1993; 341: 643-647.
93. Damas P, Reuter A, Gysen P, Demonti J, Lamy M, Franchimont P. Tumour necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989; 17: 975-978.
94. Miller AB, Foley NM, Singer M, Johnson N McI, Meager A, Rook GAW. Tumour necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome. Lancet 1989; ii: 712-714.
95. Piguet PF, Ribaux C, Karpuz V, Grau GE, Kapanci Y. Expression and localisation of tumour necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol 1993; 143: 651-655.
96. Piguet PF, Collart Ma, Grau GE, Sappino A-P, Vassalli P. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature 1990; 344: 245-247.
97. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J 1994; 7: 515-518.
98. Gearing AJH, Beckett P, Christodoulou M et al. Processing of tumour necrosis factor- precursor by metalloproteinases. Nature 1994; 370: 555-557.
99. McGeehan GM, Becherer JD, Bast RC et al. Regulation of tumour necrosis factor-processing by a metalloproteinase inhibitor. Nature 1994; 370: 558-561.
100. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice. Thorax 1993; 48: 959-966.
101. Laurent GJ, Coker RK, McAnulty RJ. TGF-β antibodies: a novel treatment for pulmonary fibrosis? Thorax 1993; 48: 953-954.
102. Editorial. Lung Transplantation. Lancet 1992; 339: 1021-1022.
103. Tsang V, Hudson ME, Yacoub MH. Lung transplantation for cystic fibrosis. Brit Med Bull 1992; 48: 949-971.
104. Hosenpud JD, Richard JN, Breen TJ, Daily OP. The registry of the international society for heart and lung transplantation: eleventh official report-1994. J Heart Lung Transplant 1994; 13: 561-570.
105. Levy RD, Guerraty AJ, Yacoub MH. Prolonged survival after heart-lung transplantation in systemic lupus erythematosus. Chest 1993; 104: 1903-1905.
106. Kramer MR. Bronchiolitis obliterans following heartlung and lung transplantation. Respir Med 1994; 88: 9-15.
107. Clelland CA, Higenbottam TW, Stewart S, Scott JP, Wallwork J. The histological changes in transbronchial biopsy after treatment of acute lung rejection in heart-lung transplant. J Pathol 1990; 161: 105-112.
108. Adams DH, Cochrane AD, Khaghani A, Smith JD, Yacoub MH. Retransplantation in heart-lung recipients with obliterative bronchiolitis. J Thorac Cardiovasc Surg 1994; 107: 450-459.
109. Novick RJ, Andreassian B, Schaffers HJ et al. Pulmonary retransplantation for obliterative bronchiolitis - intermediate-term results of a North American-European series. J Thorac Cardiovasc Surg 1994; 107: 755-763.
110. Whitehead B, Rees P, Sorensen, et al. Incidence of obliterative bronchiolitis after heart-lung transplantation in children. J Heart Lung Transplant 1993; 12; 903-908.
111. Sharples LD, Scott JP, Dennis C et al. Risk factors for survival following combined heart-lung transplantation. Transplantation 1994; 57: 218-223.
112. Thomson AW, Starzl TE. New immunosuppressive drugs: mechanistic insights and potential therapeutic advances. Immunol Rev 1993; 136: 71-98.
113. Starzl TE. Cell migration and chimerism - a unifying concept in transplantation - with particular reference to HLA matching and tolerance induction. Transplantation Proc 1993; 25: 8-12.
114. Starzle TE, Demetris AJ, Murase N, Thomson AW, Truco M, Ricordi C. Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today 1993; 14: 326-332.
115. Springall DR, Polak JM, Howard L et al. Persistence of intrinsic neurones and possible phenotypic changes after extrinsic denervation of human respiratory tract by heart-lung transplantation. Am Rev Respir Dis 1990; 141: 1538-1546.
116. Herve P, Picard N, Le Roy Ladurie M et al. Lack of bronchial hyperresponsiveness to methacholine and to isocapnic dry air hyperventilation in heart/lung and double-lung transplant. Am Rev Respir Dis 1992; 145: 1503-1505.
117. Rogers DF, O'Connor BJ. Airway hyperresponsiveness: relation to asthma and inflammation? Thorax 1993; 48: 1095-1096.
118. Hathaway TJ, Higenbottam TW, Morison JFJ, Clelland CA, Wallwork J. Effects of inhaled capsaicin in heart-lung transplant patients and asthmatic subjects. Am Rev Respir Dis 1993; 148: 1233-1237.
119. Corns PA, Dark JH. Aetiology of asthma: lessons from lung transplantation. Lancet 1993; 341: 1369-1371.